Details for New Drug Application (NDA): 210763

NDA 210763 describes SODIUM NITROPRUSSIDE, which is a drug marketed by Abraxis Pharm, Amneal, Amphastar Pharms Inc, Avet Lifesciences, Baxter Hlthcare, Be Pharms, Caplin, Chartwell Rx, Cipla, Dr Reddys, Epic Pharma Llc, Eugia Pharma, Micro Labs, Mylan Labs Ltd, Nexus, Norvium Bioscience, Sagent Pharms Inc, Slate Run Pharma, Somerset Theraps Llc, Sun Pharm, Teva Parenteral, and Xiromed, and is included in twenty-three NDAs. It is available from fifteen suppliers. Additional details are available on the SODIUM NITROPRUSSIDE profile page.

The generic ingredient in SODIUM NITROPRUSSIDE is sodium nitroprusside. There are one thousand four hundred and seventy-two drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the sodium nitroprusside profile page.

Summary for 210763

Tradename:	SODIUM NITROPRUSSIDE
Applicant:	Mylan Labs Ltd
Ingredient:	sodium nitroprusside
Patents:	0

Pharmacology for NDA: 210763

Physiological Effect

Vasodilation

Suppliers and Packaging for NDA: 210763

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
SODIUM NITROPRUSSIDE	sodium nitroprusside	INJECTABLE;INJECTION	210763	ANDA	Mylan Institutional LLC	67457-839	67457-839-02	1 VIAL, SINGLE-DOSE in 1 CARTON (67457-839-02) / 2 mL in 1 VIAL, SINGLE-DOSE
SODIUM NITROPRUSSIDE	sodium nitroprusside	INJECTABLE;INJECTION	210763	ANDA	Mylan Institutional LLC	67457-999	67457-999-02	1 VIAL, SINGLE-DOSE in 1 CARTON (67457-999-02) / 2 mL in 1 VIAL, SINGLE-DOSE

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	INJECTABLE;INJECTION			Strength	25MG/ML
Approval Date:	Apr 17, 2018	TE:	AP	RLD:	No

Complete Access Available with Subscription